Investigators will present detailed findings from a phase 2 study assessing a tambiciclib-based regimen in patients with relapsed/refractory AML at ASH 2026.
News|Videos|June 2, 2015
Ibrutinib Improves Outcomes in CLL/SLL
Author(s)Asher A. Chanan-Khan, MD
This video examines a phase III trial of ibrutinib in combination with bendamustine and rituximab in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.
Advertisement
In this video, Asher A. Chanan-Khan, MD, of the Mayo Clinic in Jacksonville, Florida, discusses a phase III trial of ibrutinib in combination with bendamustine and rituximab in patients with previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
The trial’s results (
Advertisement
Related to this article
Advertisement
Advertisement
Trending on CancerNetwork
1
Closing the HCC Surveillance Gap in MASLD Without Cirrhosis
2
Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC
3
Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis
4
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
5